These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 30905677)

  • 21. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
    Verma V; Sprave T; Haque W; Simone CB; Chang JY; Welsh JW; Thomas CR
    J Immunother Cancer; 2018 Nov; 6(1):128. PubMed ID: 30470252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China.
    Fang W; Zhao S; Zhang Y; Ma Y; Zhao H; Zhang L
    Oncologist; 2019 Feb; 24(Suppl 1):S11-S20. PubMed ID: 30819827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study.
    Iivanainen S; Alanko T; Peltola K; Konkola T; Ekström J; Virtanen H; Koivunen JP
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):765-774. PubMed ID: 30666409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of patient-reported outcomes in advanced breast cancer clinical trials: a review of the published literature.
    Turner-Bowker DM; Hao Y; Foley C; Galipeau N; Mazar I; Krohe M; Globe D; Shields AL
    Curr Med Res Opin; 2016 Oct; 32(10):1709-17. PubMed ID: 27331272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review.
    Cook MR; Kim C
    JAMA Oncol; 2019 Jul; 5(7):1049-1054. PubMed ID: 30730549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study.
    Marques RP; Heudtlass P; Pais HL; Quintela A; Martins AP
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1719-1728. PubMed ID: 31037398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
    Schadendorf D; Dummer R; Hauschild A; Robert C; Hamid O; Daud A; van den Eertwegh A; Cranmer L; O'Day S; Puzanov I; Schachter J; Blank C; Salama A; Loquai C; Mehnert JM; Hille D; Ebbinghaus S; Kang SP; Zhou W; Ribas A
    Eur J Cancer; 2016 Nov; 67():46-54. PubMed ID: 27596353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer.
    Doumas S; Foukas PG; Economopoulou P; Kotsantis I; Psyrri A
    Oral Oncol; 2020 Jan; 100():104477. PubMed ID: 31837533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review.
    Malone E; Barua R; Meti N; Li X; Fazelzad R; Hansen AR
    Cancer Med; 2021 Aug; 10(15):5031-5040. PubMed ID: 34184416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review of the association between exercise tests and patient-reported outcomes in patients with chronic obstructive pulmonary disease.
    Punekar YS; Riley JH; Lloyd E; Driessen M; Singh SJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2487-2506. PubMed ID: 28860743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer.
    Chernyshov PV; Lallas A; Tomas-Aragones L; Arenbergerova M; Samimi M; Manolache L; Svensson A; Marron SE; Sampogna F; Spillekom-vanKoulil S; Bewley A; Forsea AM; Jemec GB; Szepietowski JC; Augustin M; Finlay AY
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):816-827. PubMed ID: 30963614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
    Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
    Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.
    Wallwiener M; Matthies L; Simoes E; Keilmann L; Hartkopf AD; Sokolov AN; Walter CB; Sickenberger N; Wallwiener S; Feisst M; Gass P; Fasching PA; Lux MP; Wallwiener D; Taran FA; Rom J; Schneeweiss A; Graf J; Brucker SY
    J Med Internet Res; 2017 Sep; 19(9):e322. PubMed ID: 28912116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of a Cancer Registry to Evaluate Patient-Reported Outcomes of Immune Checkpoint Inhibitors.
    Jim HSL; Eisel SL; Hoogland AI; Shaw S; King JC; Dicker AP
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G).
    Smith AB; Cocks K; Parry D; Taylor M
    Qual Life Res; 2014 Apr; 23(3):971-6. PubMed ID: 24097080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma.
    Gough N; Koffman J; Ross JR; Riley J; Judson I
    PLoS One; 2019; 14(9):e0210731. PubMed ID: 31557183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Tan PS; Aguiar P; Haaland B; Lopes G
    Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. State of the science in ovarian cancer quality of life research: a systematic review.
    Hess LM; Stehman FB
    Int J Gynecol Cancer; 2012 Sep; 22(7):1273-80. PubMed ID: 22872168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
    Bordoni R; Ciardiello F; von Pawel J; Cortinovis D; Karagiannis T; Ballinger M; Sandler A; Yu W; He P; Matheny C; Felizzi F; Rittmeyer A
    Clin Lung Cancer; 2018 Sep; 19(5):441-449.e4. PubMed ID: 30017645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
    Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.